Furious Seasons again has a detailed analysis of more Zyprexa findings from his ongoing examination of the Zyprexa documents (it’s a long essay, but worth the read when you have a few minutes). This most recent analysis focuses on how Eli Lilly spent considerable effort marketing Zyprexa as an appropriate medication for “complex mood” disorders such as bipolar disorder and long-term use. This despite significant ongoing concerns from doctors around the country about Zyprexa and weight gain and hyperglycemia.

Eli Lilly wanted to position Zyprexa as a reasonable alternative to the long-standing, standard maintenance treatments for bipolar disorder, generic lithium (which is inexpensive, safe, and a well-known side effect profile) or Depakote (a newer mood stabilizer which is fairly inexpensive and often more effective than lithium for many people). The challenge is that Zyprexa’s chemical mechanisms are significantly different than either lithium or Depakote because it is an atypical antipsychotic medication. The other problem was apparently with people gaining significant amounts of weight and coming down with diabetes, two side effects which can be fairly debilitating to sales if widely known and disseminated.

It also appears Eli Lilly was pretty aggressive in its off-label marketing efforts. “Off-label” use of a medication is any use of a medication for which it was not specifically approved for by the FDA. This is a fairly common and standard practice amongst doctors, who find information in newly published research or through discussions with other doctors about off-label uses for a medication. But it is generally understood that pharmaceutical companies cannot market a medication for off-label uses to doctors. Off-label use is supposed to be a completely informal, clinically-driven process, not a marketing one.

 


Comments


View Comments / Leave a Comment

This post currently has 1 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2007
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2007). Zyprexa Marketed for Long-term Bipolar Use. Psych Central. Retrieved on September 22, 2014, from http://psychcentral.com/blog/archives/2007/02/21/zyprexa-marketed-for-long-term-bipolar-use/

 

Recent Comments
  • Valerie A. Klaassen: Yes, it would be nice to close the JRC down due to horrible treatment. It should not stay opened...
  • Bea: Giving life is a gift. Ideally, babies like to have a mom and dad, but in the US culture it is not easy to...
  • Hal Lyon: I find this to be one of the more brilliant self discoveries I have ever heard a person make! The...
  • TopBlue: I too hear a voice who is constantly wanting to talk about ‘himself’ (very narcissistic boring...
  • Crant: Why sometimes antidepressants do not work is because the problem they are supposed to correct is not there. We...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code